A Long-term, Multicenter, Single-arm, Open-label Extension of the SERENADE Study, to Assess the Safety and Efficacy of Macitentan in Subjects With Heart Failure With Preserved Ejection Fraction and Pulmonary Vascular Disease
Phase of Trial: Phase II
Latest Information Update: 29 Jan 2019
At a glance
- Drugs Macitentan (Primary)
- Indications Heart failure
- Focus Therapeutic Use
- Acronyms SERENADE OL
- Sponsors Actelion Pharmaceuticals
- 27 Dec 2018 Status changed from not yet recruiting to recruiting.
- 19 Dec 2018 Planned initiation date changed from 1 Dec 2018 to 21 Dec 2018.
- 29 Oct 2018 New trial record